Response to "Lupus anticoagulant is frequent in patients with Covid-19" (JTH-2020-00483)

J Thromb Haemost. 2020 Aug;18(8):2065-2066. doi: 10.1111/jth.14890. Epub 2020 Jun 25.

Abstract

We appreciate the opportunity to respond to the letter from Dr. Inès Harzallah, et al. Antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin and anti–β2‐glycoprotein I have also been performed in dozens of our patients, however, very few of them got positive results, we don't think that antiphospholipid antibody exists universally in COVID‐19 patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter [1] also seem to meet the International Society on Haemostasis and Thrombosis (ISTH) criteria of disseminated intravascular coagulation [2], the causality between antiphospholipid antibodies and thrombosis in these cases is still uncertain.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antiphospholipid Syndrome*
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections*
  • Humans
  • Lupus Coagulation Inhibitor*
  • Male
  • Pandemics*
  • Pneumonia, Viral*
  • Prostate
  • SARS-CoV-2

Substances

  • Lupus Coagulation Inhibitor